206
Participants
Start Date
September 30, 2016
Primary Completion Date
January 11, 2019
Study Completion Date
January 18, 2019
placebo
linagliptin
background therapy
insulin with or without metformin
Tianjin Medical University General Hospital, Tianjin
China-Japan Friendship Hospital, Beijing
Beijing Tongren Hospital, Beijing
The General Hospital of Chinese People's Armed Police Forces, Beijing
Shengjing Hospital of China Medical University, Shengyang
First Hospital of Jilin University, Changchun
Siping Central People's Hospital, Siping
Centre Hospital of Putuo District, Shanghai, Shanghai
Shanghai Tenth People's Hospital, Shanghai
Yangpu Hospital, Tongji University, Shanghai
Nanjing First Hospital, Nanjing
Affiliated Hospital of Jiangsu University, Zhenjiang
The First Affiliated Hospital of Soochow University, Suzhou
General Hospital of Jinan Military Area, Jinan
The affiliated hospital of medicalcollege qingdao university, Qingdao
Nankai University Affiliated Hospital, Tianjin
The 2nd Hospital of Tianjin Medical University, Tianjin
The Affiliated Hospital of Hangzhou Normal University, Hangzhou
No.900 Hospital of PLA Joint Logistics Support Force, Fuzhou
First Affiliated Hospital of Xiamen University, Xiamen
the first people hospital of Yue Yang, Yueyang
Renmin Hospital of Wuhan University, Wuhan
Third Affiliated Hospital of Guangzhou Medical University, Guangzhou
Second Hospital Affiliated to Shantou Medical University, Shantou
The Affiliated Hospital of Guizhou Medical University, Guiyang
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Boehringer Ingelheim
INDUSTRY